Fig. 2. Substrate selection (A) Amount of cLL detected using an endpoint assay, monitoring BtCDPS preference for different tRNALeu isoacceptors. There is no significant difference between tRNALeu isoacceptors. The BtCDPSS33C mutant was also similarly as active as wild type under assay conditions. (B) Products produced by BtCDPS. Chromatogram of the extracted mass for each product. Graph shows the integrated peak area for each product. (C) Results obtained when the assay was performed in the presence of either a single amino acid (leucine, cyclo-penta-alanine or tri-fluoroleucine) or a mixture (cyclo-penta-alanine and trifluoroleucine). Leucine was used as a positive control in this experiment.
